scholarly journals Safety of Peanut (Arachis hypogaea) Allergen Powder-dnfp in Children and Teenagers With Peanut Allergy: A Pooled Summary of Phase 3 and Extension Trials

2021 ◽  
Author(s):  
Kari R. Brown ◽  
James Baker ◽  
Andrea Vereda ◽  
Kirsten Beyer ◽  
A. Wesley Burks ◽  
...  
Keyword(s):  
Arachis Hypogaea ◽  
Peanut Allergy ◽  
Phase 3

scholarly journals Safety of Peanut (Arachis Hypogaea) Allergen Powder-dnfp in Children and Teenagers With Peanut Allergy: Pooled Analysis From Controlled and Open-Label Phase 3 Trials

2021 ◽  
Vol 147 (2) ◽  
pp. AB106
Author(s):  
Thomas Casale ◽  
A. Wesley Burks ◽  
James Baker ◽  
Jonathan O’B Hourihane ◽  
Kirsten Beyer ◽  
...  
Keyword(s):  
Arachis Hypogaea ◽  
Peanut Allergy ◽  
Pooled Analysis ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase

Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

2020 ◽  
Vol 4 (10) ◽  
pp. 728-739
Author(s):  
Jonathan O'B Hourihane ◽  
Kirsten Beyer ◽  
Allyah Abbas ◽  
Montserrat Fernández-Rivas ◽  
Paul J Turner ◽  
...  
Keyword(s):  
Peanut Allergy ◽  
Oral Immunotherapy ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Double Blind

Safety and efficacy comparison : ARTEMIS and PALISADE phase 3 studies of AR101 in peanut allergy

2021 ◽  
Vol 61 (5) ◽  
pp. 339-340
Author(s):  
A. Deschildre ◽  
E.R. Sher ◽  
J.O.B. Hourihane ◽  
W.W. Carr ◽  
K. Beyer ◽  
...  
Keyword(s):  
Peanut Allergy ◽  
Phase 3 ◽  
Safety And Efficacy

P303 SAFETY AND EFFICACY COMPARISON: ARTEMIS AND PALISADE PHASE 3 STUDIES OF AR101 IN PEANUT ALLERGY

2019 ◽  
Vol 123 (5) ◽  
pp. S47-S48
Author(s):  
E. Sher ◽  
J. Hourihane ◽  
W. Carr ◽  
K. Beyer ◽  
N. Griffin ◽  
...  
Keyword(s):  
Peanut Allergy ◽  
Phase 3 ◽  
Safety And Efficacy

Efficacy and Safety of AR101 in Peanut Allergy: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)

2018 ◽  
Vol 141 (2) ◽  
pp. AB400
Author(s):  
Stacie M. Jones ◽  
Kirsten Beyer ◽  
A. Wesley Burks ◽  
Thomas B. Casale ◽  
Jonathan O'B. Hourihane ◽  
...  
Keyword(s):  
Peanut Allergy ◽  
Controlled Trial ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Longer-Term Safety and Efficacy Measures of AR101 Oral Immunotherapy for Peanut Allergy: Results from a Phase 3 Follow-On Study

2019 ◽  
Vol 143 (2) ◽  
pp. AB256 ◽  
Author(s):  
Tara F. Carr ◽  
Wayne G. Shreffler ◽  
Noelle M. Griffin ◽  
Karin Rosén ◽  
Rezi Zawadzki ◽  
...  
Keyword(s):  
Peanut Allergy ◽  
Oral Immunotherapy ◽  
Phase 3 ◽  
Safety And Efficacy ◽  
Efficacy Measures

scholarly journals Impact of Peanut Allergy on Quality of Life: Baseline Results from PALISADE, a Phase 3, Double-Blind, Placebo-Controlled Trial for AR101 Oral Immunotherapy

2019 ◽  
Vol 143 (2) ◽  
pp. AB155
Author(s):  
Julie Wang ◽  
Douglas T. Johnston ◽  
Jay A. Lieberman ◽  
Christine Birchwood ◽  
Sarah Acaster ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peanut Allergy ◽  
Controlled Trial ◽  
Oral Immunotherapy ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Peanut (Arachis hypogaea) Allergen Powder-dnfp: The First FDA-approved Oral Immunotherapy for Desensitization of Peanut Allergy in Children

2021 ◽  
Vol 26 (7) ◽  
pp. 669-674
Author(s):  
Sarah S. Smith ◽  
Olga Hilas
Keyword(s):  
Health Care ◽  
Health Care Professional ◽  
Arachis Hypogaea ◽  
Peanut Allergy ◽  
Adverse Reactions ◽  
Oral Immunotherapy ◽  
Dose Titration ◽  
Allergic Reactions ◽  
Stepwise Approach ◽  
Dermatologic Manifestations

Peanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia, Aimmune™ Therapeutics, Inc.; Brisbane, CA) is the first FDA-approved oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, in patients with peanut allergy. It may be initiated in individuals 4 to 17 years of age and continued for maintenance in those 4 years of age and older. Initiation and dose titration require a stepwise approach and the supervision of a health care professional. Patients taking Peanut (Arachis hypogaea) Allergen Powder-dnfp should also follow a peanut-avoidant diet. In addition, patients should have an injectable epinephrine product in case of drug-related anaphylaxis. Commonly reported adverse reactions include gastrointestinal, respiratory, and dermatologic manifestations that are frequently associated with allergic reactions.

Sign in / Sign up

Export Citation Format

Share Document